Serologicals raises $127m in follow-on offering:
This article was originally published in Clinica
Executive Summary
Nasdaq-listed Serologicals has raised $126.8m in a public offering of shares that it expects will yield net proceeds to the company of $91.4m. Shares were also sold by stockholders, who will receive proceeds of around $29.7m. The company, which provides biological products to life science companies and institutions and runs the world's highest-volume production plant for monoclonal antibodies for use in diagnostics, says the proceeds may be used for strategic acquisitions. Approximately $80m will be used to repay debt, however. In October, Atlanta, Georgia-based Serologicals acquired Upstate Group, a maker of drug screening and drug target validation products, for $205m.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.